ERBB2 and cancer: In conclusion, we have designed a novel HER2-targeting ADC, mAb104-DX8951, which has shown great potential to respond to trastuzumab-resistant HER2-positive cancers, low HER2-expressing cancers, as well as HER2 overexpressing cancers.